Cook's Zilver PTX stent
This article was originally published in The Gray Sheet
Executive Summary
Cook Medical submits PMA application to FDA for its Zilver PTX paclitaxel-eluting stent to treat peripheral arterial disease in the superficial femoral artery. The polymer-free, self-expanding nitinol stent debuted in Europe last fall. Recently reported results of a prospective, single-arm study showed that at 12 months, freedom from target lesion revascularization was 90.5% (1"The Gray Sheet" May 17, 2010)
You may also be interested in...
Research In Brief
Leadless ICD: Cameron Health's leadless S-ICD system, the first minimally invasive, subcutaneous implantable cardioverter defibrillator for the treatment of sudden cardiac arrest, detected 100% of induced and spontaneous episodes of irregular heart rhythms, according to data from four studies appearing online in the New England Journal of Medicine May 12, in conjunction with the HRS meeting. S-ICD implantation is simpler because it does not require transvenous lead insertion, the firm notes. "These studies suggest that the S-ICD System is a viable alternative that may overcome some of the problems associated with transvenous ICDs in certain patients," said Cameron Health co-founder and lead study author Gust Bardy, M.D., Seattle Institute for Cardiac Research. The firm began a pivotal trial March 18 to support U.S. approval of the device (1"The Gray Sheet" March 29, 2010)
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.